ArticleScientific reports2025
Dysprosium, cerium, indium, yttrium, and lutetium as emerging contributors to oxidative stress in polycystic ovary syndrome.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ruthenium and recurrent pregnancy loss: insights into oxidative and genotoxic effects.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
To investigate the role of Dysprosium (Dy), Cerium (Ce), Indium (In), Yttrium (Y), and Lutetium (Lu) in relation to oxidative stress (OS) and their potential alterations in polycystic ovary syndrome (PCOS) females. This case-control study included two groups: Healthy controls (50) and PCOS cases (56). Serum levels of Dy, Ce, In, Y, and Lu were quantified using Inductively Coupled Plasma Mass Spectrometry (ICP-MS). OS was evaluated by measuring serum levels of malondialdehyde (MDA), glutathione (GSH), and superoxide dismutase (SOD). Furthermore, Pearson's correlation was performed to investigate the correlation between rare earth elements (REEs) and OS markers and differences in correlation strength between the PCOS and control groups were assessed using Fisher's z-test. PCOS subjects exhibited markedly higher concentrations of Dy, Ce, In, and Y than those in the control group (P < 0.05). The analysis of OS biomarkers revealed elevated MDA levels in the PCOS group, indicating enhanced lipid peroxidation, alongside significantly reduced antioxidant capacity (GSH and SOD) (P < 0.001). Pearson's correlation demonstrated significant positive associations between higher Dy, Ce, and Y levels and increased MDA levels (P < 0.05). Additionally, a significant negative correlation was observed between In and Y and the antioxidant markers GSH and SOD (P < 0.05), with Ce also showing an inverse association with SOD (P < 0.05). Fisher's z-test further confirmed significant differences in correlation strength between the PCOS and control groups for Dy-MDA (z = 2.01, P = 0.031), Ce-MDA (z = 1.78, P = 0.037), In-GSH (z = - 2.24, P = 0.025), and In-SOD (z = - 2.39, P = 0.017). Moreover, significant correlations were found between Dy and Y (r = 0.41, P = 0.003), Ce and In (r = 0.41, P = 0.002), Ce and Y (r = 0.53, P < 0.001), and In and Y (r = 0.70, P < 0.001), suggesting interconnected roles of Dy, Ce, In, and Y in PCOS. These findings point to a potential link between OS and REE exposure in the development of PCOS. They suggest that metal-induced oxidative damage could be a key contributor to its pathophysiology. The study underscores the need for deeper investigation into environmental factors affecting reproductive health and for identifying strategies to mitigate these risks in women with PCOS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.